Clinical pharmacogenomics: applications in pharmaceutical RD
| Autor: | Ronald M Norton |
|---|---|
| Rok vydání: | 2001 |
| Předmět: |
Pharmacology
education.field_of_study medicine.medical_specialty business.industry Drug discovery Population Phases of clinical research Biotechnology Drug metabolizing enzymes Drug development Pharmacogenomics Drug Discovery Medicine business education Intensive care medicine Pharmacogenetics Pharmaceutical industry |
| Zdroj: | Drug discovery today. 6(4) |
| ISSN: | 1878-5832 |
| Popis: | Within the pharmaceutical industry, the application of clinical pharmacogenomics promises to enhance the discovery of drug response markers, reduce the size and expense of clinical drug trials and provide a new tool for addressing regulatory approval issues. Today, pharmacogenomics is primarily applied early in clinical drug development by prospective genotyping in Phase I trials, to ensure that a subject population is representative with respect to drug metabolism phenotypes. The banking of genetic material from later stage trials for retrospective studies on drug response is becoming more frequent, but is not yet standard in the industry. This article provides an overview of the driving forces that are encouraging pharmacogenomic strategy development in the pharmaceutical industry, and the significance of polymorphisms in drug metabolizing enzymes (DMEs) and target proteins. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full Text from ScienceDirect